The three most prominent pharmacological approaches to longevity differ fundamentally in what they target: senolytics clear aged, damaged cells outright; mTOR inhibitors dial back a central growth-signaling pathway; and NAD+ precursors replenish a cofactor that declines with age. A recent review of emerging anti-aging pharmacotherapy classifies these strategies alongside senomorphics and metabolic modifiers like metformin, and finds them at markedly different stages of clinical development. Here is how each works, what compounds represent it, and where the human evidence stands.
Introduction to Pharmacological Longevity Interventions
Modern longevity research is organized around the "hallmarks of aging"—the accumulating molecular and cellular changes thought to drive age-related disease. As the review "Rewinding the Clock" explains, these hallmarks provide a conceptual framework for drug development, with candidate interventions sorted into five broad categories: senolytics, senomorphics, NAD+ precursors, mTOR inhibitors, and metabolic modifiers such as metformin. Each category attacks a different hallmark, which is precisely why they are not interchangeable—and why researchers increasingly see them as potentially complementary rather than competing.
Notably, none of these approaches is yet an approved anti-aging therapy. The clinical trial discussion below reflects publicly reported study activity, not a complete registry, and the mechanisms described reflect current scientific understanding, which may evolve. This article covers drugs and compounds only, not lifestyle interventions.
Senolytics: Targeting Senescent Cells
Senescent cells are cells that have stopped dividing but refuse to die. The problem is not merely their presence but their secretions: the senescence-associated secretory phenotype (SASP), which can be pro-inflammatory or immunosuppressive depending on cell type and timing. Persistent accumulation of these cells is implicated in tissue dysfunction, chronic inflammation, and age-related diseases, even though transient senescence plays beneficial roles in tissue repair and tumor suppression.
Senolytics work by exploiting a weakness: senescent cells upregulate pro-survival and anti-apoptotic pathways—SRC kinases, PI3K-AKT signaling, heat shock proteins, serpines, and BCL-2-related proteins—to survive in a cytotoxic environment they themselves create. Senolytic drugs aim to switch those pro-survival pathways off, selectively inducing apoptosis in the senescent cells. Among the most studied candidates is Navitoclax, a BCL-2 family inhibitor that disrupts BCL-2's interactions with its binding partners. Dasatinib combined with quercetin is another widely cited senolytic pairing.
The clinical picture is early and mixed. Navitoclax has demonstrated proof-of-concept activity but, as Selvita's drug-discovery scientists note, faces limitations in selectivity and safety—it induces apoptosis in non-senescent cells too, and does not act on all senescent cell types. It remains unapproved as a therapeutic, with ongoing trials in indications including thrombocythemia and myelofibrosis rather than aging itself.
mTOR Inhibitors: Modulating Cellular Metabolism
The mTOR pathway is a central regulator of cell growth and proliferation, and its inhibition is associated with lifespan extension in organisms from mice upward. The flagship compound is rapamycin, an mTOR kinase inhibitor with immunosuppressive and antiproliferative properties, along with its analogs, the so-called rapalogs. Rapamycin and rapalogs also suppress the SASP by inhibiting mTOR, and appear to extend healthspan and lifespan in mice—one research group has suggested rapamycin extends mouse lifespan partly by suppressing cancer development.
On the clinical side, the Interventions Testing Program has identified rapamycin and the antidiabetic drug acarbose as longevity drug candidates currently under clinical investigation. The mechanism by which these candidates prolong animal lifespan remains, as the clinical-studies review puts it, unclear. Rapamycin's established use is as an immunosuppressant, and that immunosuppressive profile is the class's most familiar safety consideration.
NAD+ Precursors: Boosting Cellular Energy and Repair
NAD+ (nicotinamide adenine dinucleotide) is a cofactor central to metabolic processes and sirtuin activity, and its levels decline with age. Rather than killing cells or blocking growth signals, NAD+ precursors simply resupply the raw material: nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) are direct precursors that cells convert into NAD+.
This replenishment strategy is the most consumer-accessible of the three classes—NMN and NR are widely sold as supplements—but accessibility is not the same as proven efficacy for lifespan. The review literature treats NAD+ precursors as a distinct category with active preclinical and translational work, and human trials to date have focused on NAD+ levels and age-related conditions rather than on lifespan or healthspan endpoints. Readers should treat marketing claims around these compounds with the caution appropriate to a field still establishing its clinical footing.
The Future of Longevity: Synergistic Approaches
Because the three classes target different hallmarks, the next frontier is combining them. The "Rewinding the Clock" review reports that drugs combining mTOR inhibitors with metformin, NAD+ precursors, or senolytics—compounds that activate AMPK, promote autophagy, or restore insulin sensitivity—are being investigated to maximize therapeutic advantage while reducing side effects.
A concrete illustration comes from Washington University School of Medicine, where Tim R. Peterson's laboratory developed BIOIO-1001, a pharmaceutical that modulates both the NAD+ and mTOR pathways—two pathways the researchers linked to lipid metabolism through genetic analysis of human cells. In mice, BIOIO-1001 reduced liver enzymes associated with scarring in non-alcoholic steatohepatitis and extended lifespan without paralysis in amyotrophic lateral sclerosis models. The work reflects the geroscience hypothesis: that treating an underlying aging process should prevent multiple age-related diseases at once. Whether these mouse results translate to humans remains untested.
Comparative Overview of Longevity Drug Classes
The table below distills the three classes into their fundamental approach and scientific maturity, so you can see at a glance how differently each one attacks aging.
| Drug Class | Mechanism of Action | Example Compounds | Clinical Development Stage |
|---|---|---|---|
| Senolytics | Selectively induce apoptosis in senescent cells by targeting their pro-survival pathways (e.g., BCL-2 family, SRC kinases) | Dasatinib + quercetin; Navitoclax (BCL-2 family inhibitor) | In clinical trials for age-related conditions; Navitoclax in trials for thrombocythemia and myelofibrosis, not yet approved |
| mTOR inhibitors | Inhibit the mTOR pathway, regulating cell growth and proliferation and suppressing the SASP | Rapamycin and rapalogs; acarbose identified as a longevity candidate under investigation | Rapamycin and acarbose under clinical investigation for longevity potential; rapalogs in trials |
| NAD+ precursors | Replenish cellular NAD+ levels, which decline with age and support metabolic processes and sirtuin activity | Nicotinamide mononucleotide (NMN); nicotinamide riboside (NR) | Active preclinical and translational work; human studies focused on NAD+ levels and age-related conditions rather than lifespan endpoints |
Two caveats belong beside this comparison. Acarbose is identified as a longevity drug candidate under investigation, but the cited evidence does not classify it as an mTOR inhibitor—it is an antidiabetic drug. And the senolytics row reflects the sharpest maturity contrast: a class with real proof-of-concept activity but acknowledged selectivity and safety limitations, versus mTOR inhibitors' stronger animal lifespan data and NAD+ precursors' earlier-stage human evidence.
Navigating the Longevity Landscape: Future Directions
Researchers and investors should consider the distinct mechanisms and clinical maturity of senolytics, mTOR inhibitors, and NAD+ precursors, while also recognizing the growing potential of synergistic combination therapies. The three classes are not competing answers to one question; they are parallel answers to three different questions—how to clear damaged cells, how to restrain growth signaling, and how to restore metabolic cofactors—and their maturity differs accordingly.
The measurable indicator to watch is continued progress in clinical trials for individual drug classes and the emergence of more multi-target compounds or combination therapy trials. Navitoclax's ongoing trials, the clinical investigation of rapamycin and acarbose, and follow-up work on dual-pathway compounds like BIOIO-1001 are the concrete milestones that will determine whether pharmacological longevity moves from mouse data to human medicine. This article is not medical advice and does not endorse any specific drug or supplement.
Sources
- Rewinding the Clock: Emerging Pharmacological Strategies for Human Anti-Aging Therapy - PMC
- Cellular senescence and senolytics: the path to the clinic - PMC
- MDPI
- Senolytics & Age-Related Diseases: A New Era in Drug Discovery — Selvita
- Clinical studies with drugs and biologics aimed at slowing or reversing normal… — Exploration of Drug Science
- A New Pharmaceutical Targeting Both NAD⁺ and mTOR Pathways Shows Efficacy Against NASH and ALS





